Prosecution Insights
Last updated: April 19, 2026
Application No. 18/551,033

NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS

Non-Final OA §102
Filed
Sep 18, 2023
Examiner
SEAMAN, D MARGARET M
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novartis AG
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
2y 4m
To Grant
84%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
1063 granted / 1387 resolved
+16.6% vs TC avg
Moderate +8% lift
Without
With
+7.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
20 currently pending
Career history
1407
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
15.1%
-24.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1387 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Priority This application was filed 09/18/2023 and is a 371 of PCT/EP2022/057655 (0/23/2022) which claims foreign priority to EP 1305366.3 (03/24/2021). Claims 1-49 have been canceled. Claims 50-98 are before the Examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis ( i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 90 is rejected under 35 U.S.C. 102 (a)(2) as being anticipated by USPGPub 20170143746. Claim 90 is anticipated by the PGPub which teaches a Markush of formula (I) and claim 10. This anticipates the instant claims . Claim 90 is rejected under 35 U.S.C. 102 (a)(2) as being anticipated by US Pat 10688101 LeTiran. LeTiran teaches a Markush of compounds of formula (I) and claim 15 that anticipates the instant claim . Allowable Subject Matter Claims 50-89 and 9 1 -98 are allowed. T he closest art to the compound of claim 91 is USPGPub 20240208976 which is the instant case. The closest art to claims 92-98 is the instant case and USPGPub20250179047, which has a later filing date. The process of claims 50-88 is free of prior art. The closest art is LeTrian US Pat 10688101 which teaches a different process for making the same compound. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT D MARGARET M SEAMAN whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)272-0694 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT M-F 8am-4pm Eastern . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Andrew Kosar can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-272-0913 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Sep 18, 2023
Application Filed
Mar 29, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599135
A COMPOSITION AND METHOD FOR PREPARING N-PHENYLPYRAZOLE-1-CARBOXAMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12595234
Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications
2y 5m to grant Granted Apr 07, 2026
Patent 12595239
SUBSTITUTED ISOXAZOLINE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12590072
THYROMIMETICS
2y 5m to grant Granted Mar 31, 2026
Patent 12577207
INDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR PARTIAL AGONISTS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
84%
With Interview (+7.9%)
2y 4m
Median Time to Grant
Low
PTA Risk
Based on 1387 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month